“Approximately 46,000 people are diagnosed with AML, ALL, and MDS in the US each ... Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, said in a statement.

Immunotherapy has revolutionized the way physicians treat patients with cancer. This form of cancer treatment aims to direct the immune system toward the r | Immunology ...

why do some patients benefit from immunotherapy while others do not? The current treatment for relapsed AML, donor lymphocyte ...

“T cell engagers are an exciting area of immunotherapy that remains in the early innings of development ... targeted immune ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly ...

CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...

However, it has proven difficult to identify such specific antigens in certain cancer types, including acute myeloid leukemia (AML). AML patients are often treated using allogeneic hematopoietic ...

(Nasdaq: CERO), a leading immunotherapy company advancing the ... of the first indications for this kind of treatment? Ehrlich: AML is a deadly disease with limited treatment options.

March 27, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T ...

(Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left without hope.” ...